Son Nguyen, MD
Gastroenterology · New Iberia, LANPI 1881874899
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 33.5% of the total. That places this record below the midpoint for gastroenterology clinicians in LA, where the typical reported total is $3,631.
Across 145 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$809
- Gilead$309
- AstraZeneca$249
- Intercept Pharmaceuticals, Inc.$246
- Pfizer$224
- Boston Scientific$125
- plus $453 from 11 others
Across 12 payments — averaging $25,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$297K
- Eli Lilly Export S.A. Puerto Rico Branch$6K
What the payments were for
- Food & beverage$2,28395%
- Education$1325%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 72 | $809 |
| Gilead | 13 | $309 |
| AstraZeneca | 11 | $249 |
| Intercept Pharmaceuticals, Inc. | 5 | $246 |
| Pfizer | 14 | $224 |
| Boston Scientific | 4 | $125 |
| Nestle Healthcare Nutrition Inc. | 6 | $89 |
| Madrigal Pharmaceuticals | 2 | $83 |
| Bristol Myers Squibb | 4 | $61 |
| Baxter Healthcare | 3 | $43 |
| QOL Medical, LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Merck | 2 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,416 in reported general payments places this provider in the 35th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HarvoniLedipasvir/Sofosbuvir | 23 | $716,899 |
| StelaraUstekinumab | 23 | $634,963 |
| Humira(Cf) PenAdalimumab | 14 | $190,562 |
| LinzessLinaclotide | 235 | $151,882 |
| Dupixent SyringeDupilumab | 13 | $93,178 |
| CreonLipase/Protease/Amylase | 14 | $35,162 |
| IbsrelaTenapanor Hcl | 11 | $18,543 |
| Dexlansoprazole DrDexlansoprazole | 55 | $14,637 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 79 | $13,742 |
| TrulancePlecanatide | 22 | $12,825 |
| CholestyramineCholestyramine (With Sugar) | 40 | $3,342 |
| Omeprazole | 349 | $3,248 |
| Esomeprazole Magnesium | 182 | $3,246 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 49 | $3,095 |
| Mesalamine | 11 | $3,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadHarvoni | $309 | $716,89923 claims |
| AbbVieLinzess, Creon | $809 | $187,044249 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $14 | $13,74279 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $31 | $12,82522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in New Iberia
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
- Sarah GloverNew Orleans$274K
- Nisha LoganantharajNew Orleans$173K
- Shamita ShahNew Orleans$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.